nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—UGT1A9—Mycophenolic acid—systemic scleroderma	0.19	0.238	CbGbCtD
Dapagliflozin—UGT2B7—Mycophenolic acid—systemic scleroderma	0.179	0.225	CbGbCtD
Dapagliflozin—UGT1A9—Mycophenolate mofetil—systemic scleroderma	0.106	0.133	CbGbCtD
Dapagliflozin—UGT2B7—Mycophenolate mofetil—systemic scleroderma	0.1	0.126	CbGbCtD
Dapagliflozin—CYP1A2—Pentoxifylline—systemic scleroderma	0.0333	0.0418	CbGbCtD
Dapagliflozin—CYP1A2—Leflunomide—systemic scleroderma	0.0318	0.0399	CbGbCtD
Dapagliflozin—ABCB1—Lisinopril—systemic scleroderma	0.0292	0.0366	CbGbCtD
Dapagliflozin—CYP2C9—Leflunomide—systemic scleroderma	0.0287	0.036	CbGbCtD
Dapagliflozin—ABCB1—Captopril—systemic scleroderma	0.0218	0.0274	CbGbCtD
Dapagliflozin—CYP2D6—Captopril—systemic scleroderma	0.0206	0.0258	CbGbCtD
Dapagliflozin—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0172	0.0216	CbGbCtD
Dapagliflozin—ABCB1—Prednisone—systemic scleroderma	0.0137	0.0172	CbGbCtD
Dapagliflozin—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0103	0.0129	CbGbCtD
Dapagliflozin—CYP2C9—cardial valve—systemic scleroderma	0.00946	0.315	CbGeAlD
Dapagliflozin—CYP3A4—Prednisone—systemic scleroderma	0.00823	0.0103	CbGbCtD
Dapagliflozin—ABCB1—Methotrexate—systemic scleroderma	0.00689	0.00865	CbGbCtD
Dapagliflozin—SLC5A4—digestive system—systemic scleroderma	0.00393	0.131	CbGeAlD
Dapagliflozin—SLC5A11—tendon—systemic scleroderma	0.0034	0.113	CbGeAlD
Dapagliflozin—SLC5A1—digestive system—systemic scleroderma	0.00226	0.0751	CbGeAlD
Dapagliflozin—SLC5A1—lung—systemic scleroderma	0.00189	0.0627	CbGeAlD
Dapagliflozin—UGT2B4—lung—systemic scleroderma	0.00174	0.0578	CbGeAlD
Dapagliflozin—UGT1A9—digestive system—systemic scleroderma	0.00142	0.0473	CbGeAlD
Dapagliflozin—UGT2B7—digestive system—systemic scleroderma	0.00115	0.0381	CbGeAlD
Dapagliflozin—CYP2A6—lung—systemic scleroderma	0.000685	0.0228	CbGeAlD
Dapagliflozin—Diabetes mellitus—Mycophenolate mofetil—systemic scleroderma	0.000619	0.00357	CcSEcCtD
Dapagliflozin—Influenza—Leflunomide—systemic scleroderma	0.000618	0.00357	CcSEcCtD
Dapagliflozin—Hyponatraemia—Lisinopril—systemic scleroderma	0.000617	0.00356	CcSEcCtD
Dapagliflozin—Pain in extremity—Lisinopril—systemic scleroderma	0.000614	0.00355	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Mycophenolic acid—systemic scleroderma	0.00061	0.00352	CcSEcCtD
Dapagliflozin—Angina pectoris—Leflunomide—systemic scleroderma	0.000602	0.00347	CcSEcCtD
Dapagliflozin—ABCB1—blood vessel—systemic scleroderma	0.000597	0.0199	CbGeAlD
Dapagliflozin—Hypertension—Pentoxifylline—systemic scleroderma	0.000595	0.00344	CcSEcCtD
Dapagliflozin—Lung disorder—Methotrexate—systemic scleroderma	0.000593	0.00343	CcSEcCtD
Dapagliflozin—Influenza—Mycophenolic acid—systemic scleroderma	0.000589	0.0034	CcSEcCtD
Dapagliflozin—Infestation NOS—Azathioprine—systemic scleroderma	0.000583	0.00337	CcSEcCtD
Dapagliflozin—Infestation—Azathioprine—systemic scleroderma	0.000583	0.00337	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Pentoxifylline—systemic scleroderma	0.000583	0.00336	CcSEcCtD
Dapagliflozin—Discomfort—Pentoxifylline—systemic scleroderma	0.00058	0.00335	CcSEcCtD
Dapagliflozin—Dysuria—Leflunomide—systemic scleroderma	0.000578	0.00334	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Lisinopril—systemic scleroderma	0.000575	0.00332	CcSEcCtD
Dapagliflozin—Back pain—Mometasone—systemic scleroderma	0.000575	0.00332	CcSEcCtD
Dapagliflozin—Angina pectoris—Mycophenolic acid—systemic scleroderma	0.000574	0.00331	CcSEcCtD
Dapagliflozin—Dehydration—Lisinopril—systemic scleroderma	0.000571	0.0033	CcSEcCtD
Dapagliflozin—Pollakiuria—Leflunomide—systemic scleroderma	0.000571	0.00329	CcSEcCtD
Dapagliflozin—Thirst—Mycophenolate mofetil—systemic scleroderma	0.000565	0.00326	CcSEcCtD
Dapagliflozin—Oedema—Pentoxifylline—systemic scleroderma	0.000562	0.00325	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Pentoxifylline—systemic scleroderma	0.000562	0.00325	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Lisinopril—systemic scleroderma	0.000561	0.00324	CcSEcCtD
Dapagliflozin—Infection—Pentoxifylline—systemic scleroderma	0.000559	0.00323	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Mycophenolate mofetil—systemic scleroderma	0.000551	0.00318	CcSEcCtD
Dapagliflozin—Dysuria—Mycophenolic acid—systemic scleroderma	0.000551	0.00318	CcSEcCtD
Dapagliflozin—Infestation NOS—Leflunomide—systemic scleroderma	0.000551	0.00318	CcSEcCtD
Dapagliflozin—Infestation—Leflunomide—systemic scleroderma	0.000551	0.00318	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Lisinopril—systemic scleroderma	0.000549	0.00317	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Mycophenolate mofetil—systemic scleroderma	0.000549	0.00317	CcSEcCtD
Dapagliflozin—Skin disorder—Pentoxifylline—systemic scleroderma	0.000546	0.00315	CcSEcCtD
Dapagliflozin—Pollakiuria—Mycophenolic acid—systemic scleroderma	0.000544	0.00314	CcSEcCtD
Dapagliflozin—Fungal infection—Methotrexate—systemic scleroderma	0.000544	0.00314	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Pentoxifylline—systemic scleroderma	0.000544	0.00314	CcSEcCtD
Dapagliflozin—Angioedema—Mometasone—systemic scleroderma	0.000543	0.00314	CcSEcCtD
Dapagliflozin—Renal failure—Leflunomide—systemic scleroderma	0.000541	0.00313	CcSEcCtD
Dapagliflozin—Hyponatraemia—Mycophenolate mofetil—systemic scleroderma	0.00054	0.00312	CcSEcCtD
Dapagliflozin—Urinary tract infection—Leflunomide—systemic scleroderma	0.000535	0.00309	CcSEcCtD
Dapagliflozin—CYP1A1—skin of body—systemic scleroderma	0.000532	0.0177	CbGeAlD
Dapagliflozin—Influenza—Lisinopril—systemic scleroderma	0.000531	0.00306	CcSEcCtD
Dapagliflozin—Hypotension—Pentoxifylline—systemic scleroderma	0.000525	0.00303	CcSEcCtD
Dapagliflozin—Infestation—Mycophenolic acid—systemic scleroderma	0.000525	0.00303	CcSEcCtD
Dapagliflozin—Infestation NOS—Mycophenolic acid—systemic scleroderma	0.000525	0.00303	CcSEcCtD
Dapagliflozin—Angina pectoris—Lisinopril—systemic scleroderma	0.000517	0.00299	CcSEcCtD
Dapagliflozin—Renal failure—Mycophenolic acid—systemic scleroderma	0.000516	0.00298	CcSEcCtD
Dapagliflozin—Urinary tract infection—Mycophenolic acid—systemic scleroderma	0.000511	0.00295	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Mycophenolate mofetil—systemic scleroderma	0.000504	0.00291	CcSEcCtD
Dapagliflozin—Dehydration—Mycophenolate mofetil—systemic scleroderma	0.0005	0.00289	CcSEcCtD
Dapagliflozin—Dysuria—Lisinopril—systemic scleroderma	0.000496	0.00287	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Mycophenolate mofetil—systemic scleroderma	0.000491	0.00284	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Leflunomide—systemic scleroderma	0.000488	0.00282	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Leflunomide—systemic scleroderma	0.000486	0.00281	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Mometasone—systemic scleroderma	0.000485	0.0028	CcSEcCtD
Dapagliflozin—Urethral disorder—Leflunomide—systemic scleroderma	0.000485	0.0028	CcSEcCtD
Dapagliflozin—Infection—Mometasone—systemic scleroderma	0.000482	0.00278	CcSEcCtD
Dapagliflozin—Extravasation—Methotrexate—systemic scleroderma	0.000481	0.00278	CcSEcCtD
Dapagliflozin—Constipation—Pentoxifylline—systemic scleroderma	0.000481	0.00278	CcSEcCtD
Dapagliflozin—Angioedema—Captopril—systemic scleroderma	0.000477	0.00276	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Lisinopril—systemic scleroderma	0.000467	0.00269	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Mycophenolic acid—systemic scleroderma	0.000466	0.00269	CcSEcCtD
Dapagliflozin—Renal failure—Lisinopril—systemic scleroderma	0.000465	0.00269	CcSEcCtD
Dapagliflozin—Influenza—Mycophenolate mofetil—systemic scleroderma	0.000465	0.00269	CcSEcCtD
Dapagliflozin—Myocardial infarction—Lisinopril—systemic scleroderma	0.000464	0.00268	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Mycophenolic acid—systemic scleroderma	0.000463	0.00268	CcSEcCtD
Dapagliflozin—Urethral disorder—Mycophenolic acid—systemic scleroderma	0.000462	0.00267	CcSEcCtD
Dapagliflozin—Urinary tract infection—Lisinopril—systemic scleroderma	0.00046	0.00266	CcSEcCtD
Dapagliflozin—Angina pectoris—Mycophenolate mofetil—systemic scleroderma	0.000453	0.00262	CcSEcCtD
Dapagliflozin—Urticaria—Pentoxifylline—systemic scleroderma	0.000447	0.00258	CcSEcCtD
Dapagliflozin—Body temperature increased—Pentoxifylline—systemic scleroderma	0.000445	0.00257	CcSEcCtD
Dapagliflozin—Discomfort—Captopril—systemic scleroderma	0.000439	0.00254	CcSEcCtD
Dapagliflozin—Dysuria—Mycophenolate mofetil—systemic scleroderma	0.000435	0.00251	CcSEcCtD
Dapagliflozin—CYP1A2—digestive system—systemic scleroderma	0.000431	0.0143	CbGeAlD
Dapagliflozin—Malnutrition—Leflunomide—systemic scleroderma	0.00043	0.00249	CcSEcCtD
Dapagliflozin—Pollakiuria—Mycophenolate mofetil—systemic scleroderma	0.00043	0.00248	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Captopril—systemic scleroderma	0.000426	0.00246	CcSEcCtD
Dapagliflozin—CYP1A1—digestive system—systemic scleroderma	0.000425	0.0142	CbGeAlD
Dapagliflozin—Urinary tract disorder—Lisinopril—systemic scleroderma	0.00042	0.00242	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Prednisone—systemic scleroderma	0.000419	0.00242	CcSEcCtD
Dapagliflozin—Urethral disorder—Lisinopril—systemic scleroderma	0.000416	0.0024	CcSEcCtD
Dapagliflozin—Back pain—Leflunomide—systemic scleroderma	0.000416	0.0024	CcSEcCtD
Dapagliflozin—Infestation—Mycophenolate mofetil—systemic scleroderma	0.000415	0.00239	CcSEcCtD
Dapagliflozin—Infestation NOS—Mycophenolate mofetil—systemic scleroderma	0.000415	0.00239	CcSEcCtD
Dapagliflozin—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.000414	0.00239	CcSEcCtD
Dapagliflozin—Malnutrition—Mycophenolic acid—systemic scleroderma	0.000411	0.00237	CcSEcCtD
Dapagliflozin—CYP2C9—digestive system—systemic scleroderma	0.000409	0.0136	CbGeAlD
Dapagliflozin—Acute coronary syndrome—Mycophenolate mofetil—systemic scleroderma	0.000409	0.00236	CcSEcCtD
Dapagliflozin—Renal failure—Mycophenolate mofetil—systemic scleroderma	0.000408	0.00235	CcSEcCtD
Dapagliflozin—Myocardial infarction—Mycophenolate mofetil—systemic scleroderma	0.000406	0.00235	CcSEcCtD
Dapagliflozin—Urinary tract infection—Mycophenolate mofetil—systemic scleroderma	0.000403	0.00233	CcSEcCtD
Dapagliflozin—Hypotension—Captopril—systemic scleroderma	0.000398	0.0023	CcSEcCtD
Dapagliflozin—Back pain—Mycophenolic acid—systemic scleroderma	0.000397	0.00229	CcSEcCtD
Dapagliflozin—Vaginal infection—Methotrexate—systemic scleroderma	0.000396	0.00229	CcSEcCtD
Dapagliflozin—Angioedema—Leflunomide—systemic scleroderma	0.000393	0.00227	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.000385	0.00223	CcSEcCtD
Dapagliflozin—Body temperature increased—Mometasone—systemic scleroderma	0.000384	0.00222	CcSEcCtD
Dapagliflozin—Discomfort—Azathioprine—systemic scleroderma	0.000383	0.00221	CcSEcCtD
Dapagliflozin—Urine output increased—Methotrexate—systemic scleroderma	0.00038	0.00219	CcSEcCtD
Dapagliflozin—Neoplasm—Methotrexate—systemic scleroderma	0.00038	0.00219	CcSEcCtD
Dapagliflozin—Dizziness—Pentoxifylline—systemic scleroderma	0.000372	0.00215	CcSEcCtD
Dapagliflozin—Hypertension—Leflunomide—systemic scleroderma	0.000372	0.00215	CcSEcCtD
Dapagliflozin—Malnutrition—Lisinopril—systemic scleroderma	0.00037	0.00214	CcSEcCtD
Dapagliflozin—Infection—Azathioprine—systemic scleroderma	0.00037	0.00213	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.000368	0.00212	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.000366	0.00211	CcSEcCtD
Dapagliflozin—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.000365	0.00211	CcSEcCtD
Dapagliflozin—Constipation—Captopril—systemic scleroderma	0.000364	0.0021	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.000364	0.0021	CcSEcCtD
Dapagliflozin—Discomfort—Leflunomide—systemic scleroderma	0.000362	0.00209	CcSEcCtD
Dapagliflozin—Skin disorder—Azathioprine—systemic scleroderma	0.000361	0.00209	CcSEcCtD
Dapagliflozin—CYP1A2—lung—systemic scleroderma	0.00036	0.012	CbGeAlD
Dapagliflozin—Back pain—Lisinopril—systemic scleroderma	0.000358	0.00207	CcSEcCtD
Dapagliflozin—CYP1A1—lung—systemic scleroderma	0.000355	0.0118	CbGeAlD
Dapagliflozin—Rash—Pentoxifylline—systemic scleroderma	0.000355	0.00205	CcSEcCtD
Dapagliflozin—Hypertension—Mycophenolic acid—systemic scleroderma	0.000354	0.00205	CcSEcCtD
Dapagliflozin—Dermatitis—Pentoxifylline—systemic scleroderma	0.000354	0.00205	CcSEcCtD
Dapagliflozin—Headache—Pentoxifylline—systemic scleroderma	0.000352	0.00203	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Leflunomide—systemic scleroderma	0.000351	0.00203	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Methotrexate—systemic scleroderma	0.00035	0.00202	CcSEcCtD
Dapagliflozin—Infection—Leflunomide—systemic scleroderma	0.000349	0.00202	CcSEcCtD
Dapagliflozin—Hypotension—Azathioprine—systemic scleroderma	0.000348	0.00201	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000347	0.002	CcSEcCtD
Dapagliflozin—Polyuria—Methotrexate—systemic scleroderma	0.000347	0.002	CcSEcCtD
Dapagliflozin—Discomfort—Mycophenolic acid—systemic scleroderma	0.000345	0.00199	CcSEcCtD
Dapagliflozin—Skin disorder—Leflunomide—systemic scleroderma	0.000341	0.00197	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Leflunomide—systemic scleroderma	0.00034	0.00196	CcSEcCtD
Dapagliflozin—Angioedema—Lisinopril—systemic scleroderma	0.000338	0.00195	CcSEcCtD
Dapagliflozin—Body temperature increased—Captopril—systemic scleroderma	0.000337	0.00195	CcSEcCtD
Dapagliflozin—Oedema—Mycophenolic acid—systemic scleroderma	0.000335	0.00193	CcSEcCtD
Dapagliflozin—Nausea—Pentoxifylline—systemic scleroderma	0.000334	0.00193	CcSEcCtD
Dapagliflozin—Infection—Mycophenolic acid—systemic scleroderma	0.000333	0.00192	CcSEcCtD
Dapagliflozin—Hypotension—Leflunomide—systemic scleroderma	0.000328	0.0019	CcSEcCtD
Dapagliflozin—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000325	0.00188	CcSEcCtD
Dapagliflozin—Malnutrition—Mycophenolate mofetil—systemic scleroderma	0.000324	0.00187	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.000324	0.00187	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000321	0.00185	CcSEcCtD
Dapagliflozin—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000313	0.00181	CcSEcCtD
Dapagliflozin—Hypotension—Mycophenolic acid—systemic scleroderma	0.000313	0.00181	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000313	0.00181	CcSEcCtD
Dapagliflozin—CYP3A4—digestive system—systemic scleroderma	0.000312	0.0104	CbGeAlD
Dapagliflozin—Discomfort—Lisinopril—systemic scleroderma	0.000311	0.0018	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Methotrexate—systemic scleroderma	0.000311	0.0018	CcSEcCtD
Dapagliflozin—CYP2D6—digestive system—systemic scleroderma	0.000307	0.0102	CbGeAlD
Dapagliflozin—Rash—Mometasone—systemic scleroderma	0.000306	0.00177	CcSEcCtD
Dapagliflozin—Dermatitis—Mometasone—systemic scleroderma	0.000306	0.00177	CcSEcCtD
Dapagliflozin—Headache—Mometasone—systemic scleroderma	0.000304	0.00176	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000303	0.00175	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000302	0.00174	CcSEcCtD
Dapagliflozin—Oedema—Lisinopril—systemic scleroderma	0.000302	0.00174	CcSEcCtD
Dapagliflozin—Constipation—Leflunomide—systemic scleroderma	0.0003	0.00173	CcSEcCtD
Dapagliflozin—Infection—Lisinopril—systemic scleroderma	0.0003	0.00173	CcSEcCtD
Dapagliflozin—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000296	0.00171	CcSEcCtD
Dapagliflozin—Body temperature increased—Azathioprine—systemic scleroderma	0.000294	0.0017	CcSEcCtD
Dapagliflozin—Skin disorder—Lisinopril—systemic scleroderma	0.000293	0.00169	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000292	0.00168	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000289	0.00167	CcSEcCtD
Dapagliflozin—Nausea—Mometasone—systemic scleroderma	0.000288	0.00166	CcSEcCtD
Dapagliflozin—Constipation—Mycophenolic acid—systemic scleroderma	0.000287	0.00165	CcSEcCtD
Dapagliflozin—Hypotension—Lisinopril—systemic scleroderma	0.000282	0.00163	CcSEcCtD
Dapagliflozin—Dizziness—Captopril—systemic scleroderma	0.000282	0.00163	CcSEcCtD
Dapagliflozin—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.00028	0.00162	CcSEcCtD
Dapagliflozin—Urticaria—Leflunomide—systemic scleroderma	0.000279	0.00161	CcSEcCtD
Dapagliflozin—Body temperature increased—Leflunomide—systemic scleroderma	0.000278	0.0016	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000277	0.0016	CcSEcCtD
Dapagliflozin—Myocardial infarction—Prednisone—systemic scleroderma	0.000275	0.00159	CcSEcCtD
Dapagliflozin—Hypersensitivity—Azathioprine—systemic scleroderma	0.000274	0.00158	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000274	0.00158	CcSEcCtD
Dapagliflozin—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000273	0.00157	CcSEcCtD
Dapagliflozin—Rash—Captopril—systemic scleroderma	0.000269	0.00155	CcSEcCtD
Dapagliflozin—Dermatitis—Captopril—systemic scleroderma	0.000268	0.00155	CcSEcCtD
Dapagliflozin—Headache—Captopril—systemic scleroderma	0.000267	0.00154	CcSEcCtD
Dapagliflozin—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000265	0.00153	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000264	0.00153	CcSEcCtD
Dapagliflozin—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000264	0.00153	CcSEcCtD
Dapagliflozin—Infection—Mycophenolate mofetil—systemic scleroderma	0.000263	0.00152	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000261	0.0015	CcSEcCtD
Dapagliflozin—Hypersensitivity—Leflunomide—systemic scleroderma	0.000259	0.00149	CcSEcCtD
Dapagliflozin—Constipation—Lisinopril—systemic scleroderma	0.000258	0.00149	CcSEcCtD
Dapagliflozin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000257	0.00148	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000256	0.00148	CcSEcCtD
Dapagliflozin—Nausea—Captopril—systemic scleroderma	0.000253	0.00146	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Prednisone—systemic scleroderma	0.000248	0.00143	CcSEcCtD
Dapagliflozin—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000247	0.00143	CcSEcCtD
Dapagliflozin—Dysuria—Methotrexate—systemic scleroderma	0.000246	0.00142	CcSEcCtD
Dapagliflozin—Dizziness—Azathioprine—systemic scleroderma	0.000246	0.00142	CcSEcCtD
Dapagliflozin—Urticaria—Lisinopril—systemic scleroderma	0.00024	0.00138	CcSEcCtD
Dapagliflozin—Body temperature increased—Lisinopril—systemic scleroderma	0.000239	0.00138	CcSEcCtD
Dapagliflozin—Infestation—Methotrexate—systemic scleroderma	0.000235	0.00136	CcSEcCtD
Dapagliflozin—Infestation NOS—Methotrexate—systemic scleroderma	0.000235	0.00136	CcSEcCtD
Dapagliflozin—Rash—Azathioprine—systemic scleroderma	0.000235	0.00135	CcSEcCtD
Dapagliflozin—Dermatitis—Azathioprine—systemic scleroderma	0.000234	0.00135	CcSEcCtD
Dapagliflozin—Headache—Azathioprine—systemic scleroderma	0.000233	0.00135	CcSEcCtD
Dapagliflozin—Dizziness—Leflunomide—systemic scleroderma	0.000232	0.00134	CcSEcCtD
Dapagliflozin—Renal failure—Methotrexate—systemic scleroderma	0.000231	0.00133	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000228	0.00132	CcSEcCtD
Dapagliflozin—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000226	0.00131	CcSEcCtD
Dapagliflozin—Hypersensitivity—Lisinopril—systemic scleroderma	0.000222	0.00128	CcSEcCtD
Dapagliflozin—Dizziness—Mycophenolic acid—systemic scleroderma	0.000222	0.00128	CcSEcCtD
Dapagliflozin—Rash—Leflunomide—systemic scleroderma	0.000221	0.00128	CcSEcCtD
Dapagliflozin—Dermatitis—Leflunomide—systemic scleroderma	0.000221	0.00128	CcSEcCtD
Dapagliflozin—Nausea—Azathioprine—systemic scleroderma	0.000221	0.00128	CcSEcCtD
Dapagliflozin—ABCB1—digestive system—systemic scleroderma	0.000221	0.00735	CbGeAlD
Dapagliflozin—Headache—Leflunomide—systemic scleroderma	0.00022	0.00127	CcSEcCtD
Dapagliflozin—Malnutrition—Prednisone—systemic scleroderma	0.00022	0.00127	CcSEcCtD
Dapagliflozin—Rash—Mycophenolic acid—systemic scleroderma	0.000211	0.00122	CcSEcCtD
Dapagliflozin—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000211	0.00122	CcSEcCtD
Dapagliflozin—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00021	0.00121	CcSEcCtD
Dapagliflozin—Headache—Mycophenolic acid—systemic scleroderma	0.00021	0.00121	CcSEcCtD
Dapagliflozin—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000209	0.00121	CcSEcCtD
Dapagliflozin—Nausea—Leflunomide—systemic scleroderma	0.000209	0.0012	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000208	0.0012	CcSEcCtD
Dapagliflozin—Urethral disorder—Methotrexate—systemic scleroderma	0.000207	0.00119	CcSEcCtD
Dapagliflozin—Angioedema—Prednisone—systemic scleroderma	0.000201	0.00116	CcSEcCtD
Dapagliflozin—Dizziness—Lisinopril—systemic scleroderma	0.0002	0.00115	CcSEcCtD
Dapagliflozin—Nausea—Mycophenolic acid—systemic scleroderma	0.000199	0.00115	CcSEcCtD
Dapagliflozin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000195	0.00113	CcSEcCtD
Dapagliflozin—Rash—Lisinopril—systemic scleroderma	0.00019	0.0011	CcSEcCtD
Dapagliflozin—Dermatitis—Lisinopril—systemic scleroderma	0.00019	0.0011	CcSEcCtD
Dapagliflozin—Hypertension—Prednisone—systemic scleroderma	0.00019	0.00109	CcSEcCtD
Dapagliflozin—Headache—Lisinopril—systemic scleroderma	0.000189	0.00109	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000186	0.00107	CcSEcCtD
Dapagliflozin—Discomfort—Prednisone—systemic scleroderma	0.000185	0.00107	CcSEcCtD
Dapagliflozin—ABCB1—lung—systemic scleroderma	0.000184	0.00614	CbGeAlD
Dapagliflozin—Malnutrition—Methotrexate—systemic scleroderma	0.000184	0.00106	CcSEcCtD
Dapagliflozin—Nausea—Lisinopril—systemic scleroderma	0.000179	0.00104	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Prednisone—systemic scleroderma	0.000179	0.00104	CcSEcCtD
Dapagliflozin—Oedema—Prednisone—systemic scleroderma	0.000179	0.00104	CcSEcCtD
Dapagliflozin—Infection—Prednisone—systemic scleroderma	0.000178	0.00103	CcSEcCtD
Dapagliflozin—Back pain—Methotrexate—systemic scleroderma	0.000178	0.00103	CcSEcCtD
Dapagliflozin—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000175	0.00101	CcSEcCtD
Dapagliflozin—Skin disorder—Prednisone—systemic scleroderma	0.000174	0.00101	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Prednisone—systemic scleroderma	0.000173	0.001	CcSEcCtD
Dapagliflozin—Rash—Mycophenolate mofetil—systemic scleroderma	0.000167	0.000963	CcSEcCtD
Dapagliflozin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000167	0.000962	CcSEcCtD
Dapagliflozin—Headache—Mycophenolate mofetil—systemic scleroderma	0.000166	0.000957	CcSEcCtD
Dapagliflozin—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000157	0.000907	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000155	0.000896	CcSEcCtD
Dapagliflozin—Discomfort—Methotrexate—systemic scleroderma	0.000154	0.000892	CcSEcCtD
Dapagliflozin—Constipation—Prednisone—systemic scleroderma	0.000153	0.000885	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Methotrexate—systemic scleroderma	0.00015	0.000865	CcSEcCtD
Dapagliflozin—Infection—Methotrexate—systemic scleroderma	0.000149	0.000859	CcSEcCtD
Dapagliflozin—Skin disorder—Methotrexate—systemic scleroderma	0.000146	0.00084	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000145	0.000836	CcSEcCtD
Dapagliflozin—Urticaria—Prednisone—systemic scleroderma	0.000142	0.000822	CcSEcCtD
Dapagliflozin—Body temperature increased—Prednisone—systemic scleroderma	0.000142	0.000818	CcSEcCtD
Dapagliflozin—Hypotension—Methotrexate—systemic scleroderma	0.00014	0.000808	CcSEcCtD
Dapagliflozin—Hypersensitivity—Prednisone—systemic scleroderma	0.000132	0.000763	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000129	0.000747	CcSEcCtD
Dapagliflozin—Urticaria—Methotrexate—systemic scleroderma	0.000119	0.000687	CcSEcCtD
Dapagliflozin—Dizziness—Prednisone—systemic scleroderma	0.000119	0.000684	CcSEcCtD
Dapagliflozin—Body temperature increased—Methotrexate—systemic scleroderma	0.000118	0.000684	CcSEcCtD
Dapagliflozin—Rash—Prednisone—systemic scleroderma	0.000113	0.000653	CcSEcCtD
Dapagliflozin—Dermatitis—Prednisone—systemic scleroderma	0.000113	0.000652	CcSEcCtD
Dapagliflozin—Headache—Prednisone—systemic scleroderma	0.000112	0.000648	CcSEcCtD
Dapagliflozin—Hypersensitivity—Methotrexate—systemic scleroderma	0.00011	0.000637	CcSEcCtD
Dapagliflozin—Nausea—Prednisone—systemic scleroderma	0.000106	0.000615	CcSEcCtD
Dapagliflozin—Dizziness—Methotrexate—systemic scleroderma	9.91e-05	0.000572	CcSEcCtD
Dapagliflozin—Rash—Methotrexate—systemic scleroderma	9.45e-05	0.000545	CcSEcCtD
Dapagliflozin—Dermatitis—Methotrexate—systemic scleroderma	9.44e-05	0.000545	CcSEcCtD
Dapagliflozin—Headache—Methotrexate—systemic scleroderma	9.38e-05	0.000542	CcSEcCtD
Dapagliflozin—Nausea—Methotrexate—systemic scleroderma	8.9e-05	0.000514	CcSEcCtD
